CannPal Begins Phase 2 Pilot Study for Cannabis-Derived Osteoarthritis Drug for Dogs

Share the love
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) recently announced the commencement of a Phase 2A pilot dose determination study for the company’s lead drug candidate, CPAT-01, in development for pain and inflammation control in dogs.

The clinical trial is an 8 week randomized, double-blind, placebo-controlled study to assess the effects of THC and CBD in dogs diagnosed with osteoarthritis. Sixty dogs are expected to participate in the trial.

12 veterinary clinics in Australia have been enrolled for the world first study with 6 across New South Wales (NSW) and 6 across Queensland. Dog recruitment has commenced, with canine assessments for first patients already underway in NSW.

The clinical trial material for the study was supplied by leading Canadian cannabis Company, Aphria, and first patient dosing is expected to commence in August 2019.

The Phase 2 study follows a successful Phase 1 research program which provided the company with a pre-clinical data pack for the drug candidate, including data in 59 dogs spanning across pharmacokinetics (fasted and fed), safety, inflammatory biomarkers, gene expression and early dose response data.

This data pack will be used to file the Company’s INAD (Investigational New Animal Drug) application with the FDA/CVM (Food and Drug Administration/Centre for Veterinary Medicine), which is expected to be filed in August 2019.

CannPal Animal Therapeutics Limited is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

Leave a Reply